SCHEMBL3389688

SCHEMBL3389688

O=C1CC2(CCCC2)C(=O)N1c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F

nearest known ligand 0.76

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 20/20 0.76

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14573232 0.87 PARP1 (1.00) PARP1
SCHEMBL3388026 0.83 PARP1 (0.64) PARP1
SCHEMBL3388183 0.83 PARP1 (1.00) PARP1
SCHEMBL29408705 0.83 PARP1 (0.92) PARP1
SCHEMBL863338 0.83 PARP1 (0.92) PARP1
SCHEMBL3385144 0.81 PARP1 (0.80) PARP1
SCHEMBL3388610 0.79 PARP1 (1.00) PARP1
SCHEMBL25890317 0.79 PARP1 (0.73) PARP1
SCHEMBL30132754 0.79 PARP1 (0.73) PARP1
SCHEMBL13007009 0.78 PARP1 (0.72) PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1501822-B1 PHTHALAZINONE DERIVATIVES KUDOS PHARM LTD (GB) 2010-12-15 EP disclosed
EP-1501822-B1 PHTHALAZINONE DERIVATIVES KUDOS PHARM LTD (GB) 2010-12-15 EP disclosed
US-7196085-B2 Phthalazinone derivatives KUDOS PHARMACEUTICALS LIMITED (GB) 2007-03-27 US disclosed
US-7196085-B2 Phthalazinone derivatives KUDOS PHARMACEUTICALS LIMITED (GB) 2007-03-27 US disclosed
US-7196085-B2 Phthalazinone derivatives KUDOS PHARMACEUTICALS LIMITED (GB) 2007-03-27 US disclosed
US-20040023968-A1 Phthalazinone derivatives, and their use as pharmaceuticals. In particular, the present as enzyme inhibitors KUDOS PHARMACEUTICALS LIMITED (GB) 2004-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040023968-A1 Phthalazinone derivatives, and their use as pharmaceuticals. In particular, the present as enzyme inhibitors PARP1, PARP2, PARP15 PARP1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.